QTORIN™ rapamycin has potential to become first approved therapy and standard of care for Microcystic Lymphatic Malformations in U.S.; significant commercial opportunity based on an estimated more than 30,000 individuals
Survey questions included how respondents would use AI to help their patients, and how they felt about non-dermatologists using AI to detect skin lesions.